At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials - Université de Bretagne Occidentale Access content directly
Conference Poster Year : 2018

At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials

No file

Dates and versions

hal-01950293 , version 1 (10-12-2018)

Identifiers

  • HAL Id : hal-01950293 , version 1

Cite

Rm Flipo, A. Saraux, Christophe Hudry, C Gaujoux-Viala, E Senbel, et al.. At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials. ACR/ARHP Annual Meeting, Oct 2018, Chicago, United States. 70 (suppl 10) (Abstract 601), Arthritis Rheumatology. ⟨hal-01950293⟩
61 View
0 Download

Share

Gmail Mastodon Facebook X LinkedIn More